• English
    • Deutsch
  • English 
    • English
    • Deutsch
  • Login
View Item 
  •   Home
  • Universität Ulm / Medizin
  • Publikationen
  • View Item
  •   Home
  • Universität Ulm / Medizin
  • Publikationen
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Relevanz der AMP-aktivierten Proteinkinase als Biomarker in der Therapie des nicht-kleinzelligen Lungenkarzinoms

Thumbnail
vts_9324_14025.pdf (1001.Kb)
70 S.
Veröffentlichung
2014-12-23
Authors
Grams, Juliane
Dissertation


Faculties
Medizinische Fakultät
Abstract
Background: It is known for a long time, that there is an association between Diabetes mellitus and cancer diseases. Metformin as widely used antidiabetic drug could possibly have a protective effect on the development of cancer and furthermore it could be effective in therapeutic regimens. We evaluated the influence of metfomin on the AMP-activated protein kinase in non-small cell lung cancer xenografts. We examined if there is a supportive effect of metformin on the response on the monoclonal EGFR antibody Cetuximab in non-small cell lung cancer. Methods: Xenografts with non-small cell lung cancer were treated with cetuximab and metformin followed by measurement of the tumor growth. Afterwards AMPK and p70 S6k expression were determined via western blot on protein level and via rt-PCR on m-RNA level in the tumor probes. Furthermore patient data were analyzed and correlated with the tumor behavior in the xenografts. Results: Starting from 89 surgical NSCLC specimens, which were obtained from primarily diagnosed patients with early-stage tumors, 25 transplantable xenografts were established. There was no influence of metformin on tumor growth. Also there couldn`t be seen any regulation of AMPK or p70S6K in the tumors. We couldn`t show any correlation between tumor doubling time in xenografts and the overall survival, disease free survival or age of the patients. Summary: Patient derived Xenografts allow performing complex pre-clinical studies in non small cell lung cancer. Metformin didn’t influence tumor growth, the tumor response on cetuximab or regulation of AMP activated protein kinase so it doesn’t seem to have any relevance in treatment of non-small cell lung cancer.
Date created
2014
Subject headings
[GND]: Lungenkrebs | Metformin
[MeSH]: Carcinoma, non-small-cell lung; Therapy | Lung neoplasms; Therapy | Protein kinases
[Free subject headings]: Nicht-kleinzelliges Lungenkarzinom | Xenograft
[DDC subject group]: DDC 610 / Medicine & health
License
Standard
https://oparu.uni-ulm.de/xmlui/license_v3

Metadata
Show full item record

DOI & citation

Please use this identifier to cite or link to this item: http://dx.doi.org/10.18725/OPARU-3509

Grams, Juliane (2014): Relevanz der AMP-aktivierten Proteinkinase als Biomarker in der Therapie des nicht-kleinzelligen Lungenkarzinoms. Open Access Repositorium der Universität Ulm und Technischen Hochschule Ulm. Dissertation. http://dx.doi.org/10.18725/OPARU-3509
Citation formatter >



Policy | kiz service OPARU | Contact Us
Impressum | Privacy statement
 

 

Advanced Search

Browse

All of OPARUCommunities & CollectionsPersonsInstitutionsPublication typesUlm SerialsDewey Decimal ClassesEU projects UlmDFG projects UlmOther projects Ulm

My Account

LoginRegister

Statistics

View Usage Statistics

Policy | kiz service OPARU | Contact Us
Impressum | Privacy statement